Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. They are advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.